Physiomics PLC Contract Award
04 8월 2023 - 3:00PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
04 August 2023
4 August 2023
Physiomics plc
("Physiomics") or ("the Company")
Contract award
Physiomics plc (AIM: PYC), a leading mathematical modelling
company, supporting development of oncology drugs and personalised
medicine solutions, is pleased to announce that it has been awarded
a further contract by existing client Bicycle Therapeutics
("Bicycle") that it expects to be completed over the next six
months. The project involves modelling and the use of
bioinformatics data in support of target identification for
undisclosed Bicycle programs.
Physiomics CEO, Dr Jim Millen, commented: "We are delighted
that, having worked on a number of clinical stage projects with
Bicycle, we are now complementing these with a substantial project
focused on earlier stage drug development. We look forward to
working once again with Bicycle's talented team."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys. Our
approach is to derive insight from all relevant data in order to
de-risk decision making and optimise design of pre-clinical and
clinical studies. Through use of bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the
development of over 100 projects, over 40 targets and 70 drugs.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab
Therapeutics & CRUK.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUUGRUPWGMW
(END) Dow Jones Newswires
August 04, 2023 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Physiomics (LSE:PYC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024